Welcome to our dedicated page for Canopy Growth news (Ticker: CGC), a resource for investors and traders seeking the latest updates and insights on Canopy Growth stock.
Canopy Growth Corporation develops and sells cannabis products for adult-use and medical markets, with common shares trading as CGC on Nasdaq and WEED on the TSX. Company updates frequently cover Canadian brand activity across Tweed, Deelish, 7ACRES, DOJA, Deep Space and related formats including flower, pre-rolls, vapes, softgels and minor cannabinoid products.
News also centers on medical cannabis services through Canada House Clinics and the Abba Medix online channel, Storz & Bickel vaporization devices, operating and financial results, capital-structure actions, shareholder voting matters and governance changes. Canopy Growth also discloses its unconsolidated, non-controlling interest in Canopy USA as exposure to the U.S. THC market.
Canopy Growth Corporation has successfully completed its acquisition of The Supreme Cannabis Company, Inc. as of June 23, 2021. This strategic move enhances Canopy's leadership in the Canadian recreational cannabis market, increasing its market share to 18.1%. The acquisition includes Supreme's low-cost cultivation facility in Kincardine, Ontario, and is expected to yield $30 million in synergies within two years. As part of the Arrangement, Supreme shareholders receive 0.01165872 Canopy shares and $0.0001 in cash for each Supreme share.
Little Green Pharma Ltd has acquired a GMP medicinal cannabis cultivation and manufacturing facility in Denmark from Canopy Growth Corporation for C$20 million. The facility can produce over 12 tonnes of medicinal cannabis annually and enhances LGP's inventory, which currently holds about 1 tonne. This strategic acquisition allows LGP to expand into EU and global markets, with immediate plans to deliver products in Australia and Germany. The facility is expected to begin offering registered medicinal products in Denmark by early 2022, positioning LGP as a leader in the Australian medicinal cannabis sector.
Canopy Growth Corporation reported a 37% revenue growth for FY 2021, reaching $546.6 million, with significant gains in both cannabis and consumer products. The company maintains its leading position in the Canadian flower market and is making strides in the US market with new product launches, including CBD products by Martha Stewart. Canopy aims for positive Adjusted EBITDA in H2 FY 2022 and expects cost savings of $150-$200 million within 18 months. However, the company reported a net loss of $1.67 billion for the fiscal year.
On May 28, 2021, Canopy Growth Corporation (NASDAQ: CGC) announced participation in upcoming investor conferences in June 2021. Executives David Culver and Judy Hong will take part in the Piper Sandler Consumer Marketplace Conference on June 3, discussing legalization and regulatory landscapes. Rade Kovacevic will present at the Oppenheimer Consumer Growth and E-Commerce Conference on June 15, focusing on consumer insights and product innovation. Both events will be accessible via live webcast on the company's website, with replays available for 90 days.
Canopy Growth Corporation (CGC) appoints Martha Stewart as its official strategic advisor to enhance its product innovation and branding strategies. In her new role, she will provide expert counsel on product development and strategic partnerships. This appointment follows the successful launch of the Martha Stewart CBD product line, which includes wellness supplements for both humans and pets. The brand has seen significant consumer demand, with products selling out for holidays. Additionally, Canopy Growth has secured a distribution deal with Southern Glazer's Wine and Spirits to expand the reach of Martha Stewart CBD across the U.S.
Canopy Growth Corporation (TSX: WEED, NASDAQ: CGC) will announce its financial results for the fourth quarter and fiscal year 2021, concluding on March 31, 2021, before markets open on June 1, 2021. Following this announcement, a live audio webcast featuring CEO David Klein and CFO Mike Lee will take place at 10:00 AM ET on the same day. Investors can access the webcast and replay until August 30, 2021. Canopy Growth is a leading cannabis company, known for its diverse product offerings and partnerships, including one with Constellation Brands.
Canopy Growth Corporation (NASDAQ: CGC) has entered a partnership with Southern Glazer's Wine & Spirits to distribute its CBD-infused beverage, Quatreau, across the U.S. This agreement allows Canopy to leverage Southern Glazer's extensive distribution network, aiming to enhance market access for its CBD product line beginning in seven states. Quatreau, priced at $3.99 per 12-ounce can, offers 20 mg of U.S.-grown hemp-based CBD in four flavors and follows its successful launch in Canada. This move highlights Canopy's strategy to expand its presence in the booming CBD beverage market.
Canopy Growth Corporation announced a definitive agreement to acquire The Supreme Cannabis Company for approximately $435 million, offering Supreme shareholders a 66% premium per share. The deal enhances Canopy's brand portfolio by adding 7ACRES and strengthens its market position, potentially increasing its Canadian recreational market share to 13.6%. The acquisition is expected to yield cost synergies of $30 million within two years and expand Canopy's footprint in the U.S. CBD market. Shareholder approval is anticipated by June 2021.
Canopy Growth Corporation has successfully acquired Ace Valley, a prominent cannabis brand in Ontario, known for its 'Ready to Enjoy' products. This acquisition is anticipated to enhance Canopy's brand portfolio and leverage its distribution capabilities, aiming for nationwide expansion in Canada. Ace Valley's strong presence among millennial and Gen-Z consumers complements Canopy's existing offerings, enabling potential revenue growth. Canopy expects to optimize production and realize cost synergies, further solidifying its position in the cannabis market.
Canopy Growth Corporation (NASDAQ: CGC) announced a US$750 million senior secured term loan agreement with King Street Capital Management on March 18, 2021. The loan, with no amortization payments and maturing on March 18, 2026, allows for an additional US$500 million in incremental debt. The funds will enhance Canopy's balance sheet and support investments in growth initiatives, acquisitions, and capital expenditures. Following this financing, Canopy's estimated cash position as of December 31, 2020, would have been approximately CAD$2.5 billion.